Claims for Patent: 11,110,063

Summary for Patent: 11,110,063

Title:	Storage stable sincalide formulations
Abstract:	Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.
Inventor(s):	Srikanth Sundaram
Assignee:	Maia Pharmaceuticals Inc
Application Number:	US15/958,854
Patent Claims:	1. A solid composition comprising: (i) from 2.5 to 10 mcg of sincalide; (ii) from 1 to 4 mg of pentetic acid; (iii) from 15 to 45 mg of arginine hydrochloride; (iv) from 2 to 8 mg of L-methionine; (v) from 7.5 to 30 mg of L-lysine hydrochloride; (vi) from 0.02 to 1 mg of sodium metabisulfite; and (vii) from 85 to 340 mg of mannitol, wherein the solid composition comprises a pH of about 6.5 to about 7.5 when reconstituted in a pharmaceutically acceptable diluent, wherein the solid composition does not contain a phosphate buffer, wherein the solid composition does not contain a surfactant, a solubilizer, polysorbate 20, or polysorbate 80, wherein the solid composition is formulated to be reconstituted in a pharmaceutically acceptable diluent for a quantity sufficient to 2.5 to 10 mL, and wherein the solid composition maintains total impurities less than 5% after 15 months of storage at 25° C., 60% relative humidity or after 3 months of storage at 40° C., 75% relative humidity and optionally wherein the solid composition also maintains a sincalide level of at least 90% after 15 months of storage at 25° C., 60% relative humidity when tested by high-performance liquid chromatography. 2. The solid composition of claim 1, wherein the solid composition does not contain a buffer having a pKa within one unit of the pH, and wherein the solid composition also does not contain a buffer selected from the group consisting of phosphoric acid, citric acid, citrate, sulfosalicylate, acetic acid, acetate, methyl boronic acid, boronate, disodium succinate hexahydrate, lactic acid, lactate, maleic acid, maleate, potassium chloride, benzoic acid, sodium benzoate, carbonic acid, carbonate, bicarbonate, boric acid, sodium borate, sodium chloride, succinic acid, succinate, tartaric acid, tartrate, tris-(hydroxymethyl)aminomethane, N-2-hydroxyethylpiperazine, N′-2-ethanesulfonic acid, CHAPS, and any combination thereof. 3. The solid composition of claim 1, wherein the solid composition does not contain a polysorbate. 4. The solid composition of claim 1, wherein the solid composition comprises: (i) 5 mcg of sincalide; (ii) 2 mg of pentetic acid; (iii) 30 mg of arginine hydrochloride; (iv) 4 mg of L-methionine; (v) 15 mg of L-lysine hydrochloride; (vi) 0.04 mg of sodium metabisulfite; and (vii) 170 mg of mannitol. 5. The solid composition of claim 4, wherein the solid composition does not contain a polysorbate. 6. A solid composition comprising: (a) 2.5 to 10 mcg of sincalide, (b) 1 to 4 mg pentetic acid, (c) 15 to 45 mg arginine hydrochloride, (d) 2 to 8 mg methionine, (e) 7.5 to 30 mg lysine hydrochloride, (f) 0.02 to 1 mg sodium metabisulfite, and (g) 85 to 340 mg mannitol, wherein the solid composition comprises a pH from 6.5 to 7.5 when reconstituted in a pharmaceutically acceptable diluent, wherein the solid composition does not contain a phosphate buffer, wherein the solid composition does not contain a surfactant, a solubilizer, polysorbate 20, or polysorbate 80, wherein the solid composition does not contain a buffer having a pKa within one unit of the pH, and wherein the solid composition maintains total impurities of less than 5% after 15 months of storage at 25° C., 60% relative humidity or after 3 months of storage at 40° C., 75% relative humidity and optionally wherein the solid composition also maintains a sincalide level of at least 90% after 15 months of storage at 25° C., 60% relative humidity when tested by high-performance liquid chromatography. 7. The solid composition of claim 1, wherein the solid composition is a lyophilized powder. 8. A method for the treatment and/or diagnosis of gall bladder and/or pancreatic disorders, or other diagnostic imaging of a patient in need thereof comprising administering a therapeutically or diagnostically effective amount of the solid composition of claim 1 in reconstituted form to the patient. 9. A method of making the solid composition of claim 1, the method comprising: (1) mixing: (i) sincalide, (ii) pentetic acid, (iii) arginine hydrochloride, (iv) L-methionine, (v) L-lysine hydrochloride, (vi) sodium metabisulfite, (vii) mannitol, (viii) a pH adjuster, and (ix) water to form a mixture having a pH of about 6.5 to about 7.5, and (2) lyophilizing the pH-adjusted mixture. 10. The solid composition of claim 6, wherein the solid composition is a lyophilized powder. 11. The solid composition of claim 10, wherein the solid composition maintains total impurities of less than 4% and/or a sincalide level of at least 90% after 15 months of storage at 25° C., 60% relative humidity when tested by high-performance liquid chromatography. 12. The solid composition of claim 10, wherein the solid composition maintains total impurities of less than 3% and/or a sincalide level of at least 90% after 15 months of storage at 25° C., 60% relative humidity when tested by high-performance liquid chromatography. 13. A vial comprising the solid composition of claim 1. 14. A kit comprising the vial of claim 13 and a fluid portion. 15. The solid composition of claim 4, wherein the solid composition does not contain a buffer having a pKa within one unit of the pH, and wherein the solid composition also does not contain a buffer selected from the group consisting of phosphoric acid, citric acid, citrate, sulfosalicylate, acetic acid, acetate, methyl boronic acid, boronate, disodium succinate hexahydrate, lactic acid, lactate, maleic acid, maleate, potassium chloride, benzoic acid, sodium benzoate, carbonic acid, carbonate, bicarbonate, boric acid, sodium borate, sodium chloride, succinic acid, succinate, tartaric acid, tartrate, tris-(hydroxymethyl)aminomethane, N-2-hydroxyethylpiperazine, N′-2-ethanesulfonic acid, CHAPS, and any combination thereof. 16. The solid composition of claim 6, wherein the solid composition also does not contain a buffer selected from the group consisting of phosphoric acid, citric acid, citrate, sulfosalicylate, acetic acid, acetate, methyl boronic acid, boronate, disodium succinate hexahydrate, lactic acid, lactate, maleic acid, maleate, potassium chloride, benzoic acid, sodium benzoate, carbonic acid, carbonate, bicarbonate, boric acid, sodium borate, sodium chloride, succinic acid, succinate, tartaric acid, tartrate, tris-(hydroxymethyl)aminomethane, N-2-hydroxyethylpiperazine, N′-2-ethanesulfonic acid, CHAPS, and any combination thereof. 17. The solid composition of claim 1, wherein the solid composition maintains total impurities of less than 5% and a sincalide level of at least 90% for at least 18 months when stored at 25° C., 60% relative humidity. 18. The solid composition of claim 4, wherein the solid composition maintains total impurities of less than 5% and a sincalide level of at least 90% for at least 18 months when stored at 25° C., 60% relative humidity. 19. The solid composition of claim 6, wherein the solid composition maintains total impurities of less than 5% and a sincalide level of at least 90% for at least 18 months when stored at 25° C., 60% relative humidity.